



Your smart
tech partner
in natural health.

A public benefit corporation.






Our Mission

Our mission is to transform health outcomes with accessible wellness solutions powered by nature, science, and the latest innovations in tech.

Guiding Principles





AI Precision Health



Mental Health App

An all-in-one app for stress management and mental health in the modern world.

- Stress resilience and management programs
- Tele-health platform for somatic practitioners with private payor coverage



Natural Wellness App

NARA is designed to help real women transform their wellness — with natural solutions and tools that are actually backed by science.

- DNA Reports for Women
- Precision health services, coaching, and products



AI Driven Prognostics for Optimal Brain Health

A clinical decision support system that provides personalised trending data on patient brain health to support improved outcomes.

- Proprietary brain biomarker panels that provide insights on impact of alternative treatment regimens
- AI driven prognostic tracking system that analyzes impact of patient treatment regimen on symptom and biomarker changes

Private and secure data capture utilizing **PanGenomic's NaraCare.AI**



The PanGenomic product suite is powered by: NaraCare.AI

Precision health built with OpenAI

1. Capabilities —————> 2. Process —————> 3. Outcomes

Collects and stores health data from:

- Consumer app
- DNA reports
- Biomarker diagnostics
- Clinician inputs

Analyzes health data using proprietary AI algorithms to personalize service and product recommendations.


Personalization, user experience, and efficacy are enhanced to deliver better outcomes for practitioners, patients, and other wellness seekers



“Health better, naturally.”

App Features

- ☑ Proprietary women’s health genetic reports
- ☑ Precision health app with services, coaching and products
- ☑ Ability for users to get genetic counselling, health coaching and naturopathic practitioner through tele-health feature
- ☑ A unique, evidence-based **library** of natural wellness solutions





Mindleap

“Stress Better”

App Features

Mindleap empowers users to manage their mental health with:

- ☑ A **growing library** of self-guided programs (video, audio)
- ☑ In-app **tele-health dashboard** for clinical therapists, somatic practitioners, and coaches (**fee for service, insurance eligible**)
- ☑ **Geo-locational** matching of practitioners and users enables hybrid telehealth and in-person care delivery





“Better brain health with personalized analytics”



MUJN Decision Support System (DSS) Features

- ☑ Brain health quantitative tracking system that uses a proprietary diagnostic platform with our neuro and inflammatory biomarker panel
- ☑ AI Driven brain health status prognostic tracking incorporating multiple personalized health analytics
- ☑ Both patient and clinician comprehensive data tracking provides insights that are built to improve patient compliance, provide objective information on treatment efficacy and ultimately better patient outcomes

Market Opportunity for Natural Precision Health

\$211bn

Global
Digital Health
Market

\$87bn
TeleHealth

\$35bn
Health Analytics

\$117bn

Global
Complementary &
Alternative Medicine
Market

\$11bn
Herbal Supplements

\$65bn

Global Precision
Medicine
Market

\$16bn
DNA Sequencing



nara

Mindleap

MUJN

North America

24 million target users *

\$130 annual avg value

\$3.1bn Target Market

* One-half of the 12% of North Americans who use herbal remedies regularly.

Share Structure

PanGenomic Health Inc.
(CSE:NARA) (FSE:LL30)

Outstanding Shares (as at June 30, 2025)

18,200,275

Fully Diluted:

Current warrants outstanding (exercise price \$0.13)

7,500,000

Current stock options outstanding (avg exercise price of \$1.32)

1,372,400

27,072,675

Management & Directors

MEET THE DEDICATED TEAM BEHIND THE GAME-CHANGING PRODUCTS AT PANGENOMIC.



Robert Nygren

Co-Founder, Exec. Chair

Robert co-founded the biotech company Havn Life Sciences (CSE: HAVN) and served as a founding director of Psy Integrated Health Corp. He was also involved in establishing the Vancouver-based Empower Health clinic. In addition to these ventures, Robert co-founded the ETC3 Tech Centre located in the Research Campus of UBC. Prior to his involvement in these ventures, Robert served as the CEO of Epic Data and Fincentric.



Maryam Marissen

CEO

Maryam has served in almost every facet of business — as a founder, board member, consultant, and now CEO. With a natural drive to achieve, she's developed a diverse skillset, spanning consumer product marketing, private clinical services, public relations, and even social advocacy. Above all else, Maryam is committed to accessible healthcare, the democratization of natural wellness, and leveraging tech to transform the status quo.



Vincent Lum

CEO of Mujn

Vincent has over 20 years of experience, including several C-level positions, in the life sciences space. He is currently the CEO of MUJN Diagnostics, but also co-founded Cardio-digital, which was later acquired by Medtronic. Prior to that, he served as Vice President and Partner at MDS Capital and Royal Bank Venture Capital. Today, Vincent is leveraging his two decades of industry experience to inform PanGenomic's work.



Manpreet Dhillon

Director

Ms. Dhillon has over 20 years of international consulting experience with the UN system, NGOs, and governments, focusing on economic empowerment, gender equality, and stakeholder engagement. She is the founder of Veza Global, a Canadian organization helping employers and HR leaders advance diversity, equity, inclusion, and belonging. With expertise in strategic planning, EDI programs, stakeholder engagement, brand development, and leadership coaching, Ms. Dhillon holds both BBA and MA degrees.



Kaidong Zhang

CSO

An expert in integrative medicine, Kaidong has 15 years of experience in academia and industry with a background in protein engineering and medicinal chemistry. His recent R&D projects span several areas key to the work PanGenomic does, including the development of clinical diagnoses and nutraceutical products, the management of chronic disease with integrative medicine, and the creation of non-invasive diagnostic and therapeutic devices to manage select chronic health issues.



Tammy Gillis

CFO

With two decades of experience in the public markets, Tammy has a comprehensive background in finance, reporting, and the regulatory requirements of several major industries - including manufacturing, tech, biotech, and junior exploration. She has served on teams that have successfully completed financings, grant applications, and acquisition transactions, and has worked as an officer for several listed issuers.

Cautionary Statement

This presentation is confidential and is being issued by PanGenomic Health Inc. (the “Company”) for informational purposes only. Reliance on this presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This presentation may not be copied, reproduced, distributed, discussed or used without the express written consent of the Company or its advisors on its behalf, or for any other purpose than the evaluation by the recipient of a possible investment in the Company. The Company does not make any representation or warranty as to the accuracy or completeness of the information in this presentation, and the information herein may not be relied upon by you in evaluating the merits of investing in any securities referred to herein. This presentation does not contain, nor does it purport to contain, a summary of all of the material information concerning the Company or the terms and conditions of any potential investment in the Company. If and when you determine to proceed with discussions and investigations regarding a possible investment in the Company, prospective investors are urged to carry out independent investigations in order to determine their interest in investing in the Company.

In furnishing this presentation to the recipient, the Company and its advisors reserve the right to provide the same or similar information to other persons and to enter into agreements with other parties regarding the opportunity described in this presentation and to cease to provide the recipient with information on the opportunity, all without notice to the recipient. This presentation is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of securities in the United States, Canada or any other jurisdiction. No securities commission or similar authority of the United States, Canada, or any other jurisdiction has reviewed or in any way passed upon this document or the merits of the securities described herein, and any representation to the contrary is an offence. This presentation does not contain all of the information that would normally appear in a prospectus under applicable Canadian or United States securities laws. Neither the delivery of this presentation, at any time, nor any sale made pursuant hereto, will imply that the information contained herein is correct as of any time subsequent to the date set

forth on the cover page hereof or the date at which such information is expressed to be stated, as applicable, and, except as may be required by applicable law, the Company is under no obligation to update any of the information contained herein (including forward looking statements and forward looking information) or to inform the recipient of any matters of which it becomes aware that may affect any matter referred to in this presentation (including, but not limited to, any error or omission which may become apparent after this presentation has been prepared).

This presentation is not intended as an offer or solicitation with respect to the purchase or sale of any financial instrument. If a private placement of the equity securities of the Company occurs, such transaction may not be registered under the Securities Act of 1933, as amended (the “Act”), or the securities laws of any other jurisdiction, and would be conducted in reliance on exemptions from the registration requirements of the Act and other applicable laws and subject to selling and transfer restrictions.

Investing in the Company involves significant risks given the early stage nature of the Company’s business. Prior to investing in the Company, prospective investors are urged to consult with their legal, investment, accounting, tax and other advisors to determine the risks and consequences of an investment in the Company. Prospective investors should not construe the contents of this presentation as investment or legal advice.

This presentation contains certain forward-looking statements and and forward-looking information. Forward- looking statements are frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential”, “possible” “projects”, “plans,” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” or “should” occur or be achieved or their negatives or other comparable words. Any forward-looking statements made herein or made elsewhere by the Company are made solely based on information available to the Company as of the date hereof and based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, anticipated events and trends, the economy and other future conditions. As such, they are subject to inherent uncertainties, risks, assumptions and changes in circumstances that are difficult to predict (including but not limited to risks applicable to early stage ventures and cannabis organizations), and in many cases outside of the Company’s control, and you should not rely on such forward-looking statements. All statements other than statements of historical fact could be deemed forward- looking, including, but not limited to, any statements about historical results that suggest trends for the Company’s business, any statements of plans, strategies and objectives of management and any statements of expectation or belief regarding future events. “Future-oriented financial information” is forward-looking information about prospective results of operations, financial position or cash flows, based on assumptions about future economic conditions and courses of action, and presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Similarly, a “financial outlook” is forward looking information about prospective financial performance, financial position or cash flows that is based on assumptions about future economic conditions and courses of action that is not presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Future-oriented financial information and financial outlook made herein or made elsewhere by the Company are made solely based on the information available to the Company as of the date hereof and are subject to the same assumptions, risk factors and other qualifications as all other forward-looking information, and presented solely for the purpose of conveying the current anticipated expectations of the Company and may not be appropriate for any other purposes. Forward-looking statements and forward-looking information address future events and conditions and therefore involve inherent known and unknown risks and uncertainties. Actual results may differ materially from those in the forward looking statements and forward-looking information due to risks facing the Company or due to actual facts differing from the assumptions underlying its predictions. Certain of the information contained in this presentation concerning the industry and its trends and performance is based upon or derived from information provided by third-party consultants, other industry sources and our research. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of such information and has not independently verified the assumptions upon which any projections are based.



A public benefit corporation
(CSE: NARA)

Your smart
tech partner
in natural health.

info@pangenomic.com

Auditor Info:
Saturna Group Chartered Professional Accountants LLP
1605 - 1166 Alberni, Vancouver B.C. Canada, V6E 3Z3

Fiscal Year End: Dec. 31

Corporate headquarters:
102 - 3800 Wesbrook Mall Vancouver, BC, Canada, V6S 2L9